Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2025-12-02 00:00:00 ET · period of report 2025-11-28 · accession 0001643653-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-02 | 2025-11-28 | NBIX | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $35.99 | +5,970 | 50.9K | +13% | +$214.9K |
| D | 2025-12-02 | 2025-11-28 | NBIX | BENEVICH ERIC | Chief Commercial Off | S - Sale+OE | $151.74 | -5,970 | 44.9K | -12% | -$905.9K |
| D | 2025-12-02 | 2025-11-28 | NBIX | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | -5,970 | 6,860 | -47% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-28 | M | A | 5,970 | $35.99 | 50,863 | D | — | — | (F1) Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2025-11-28 | S | D | 5,970 | $151.74 | 44,893 | D | — | — | (F3) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.70 to $153.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Derivative | Incentive Stock Option | 2025-11-28 | M | D | 5,970 | $0.00 | 6,860 | D | $35.99 · — to 2026-02-05 | 5,970 Common Stock | (F4) The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026. |